Clinical Trial Update: RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe [Phase 2]

View source ↗

Summary

Phase 2 RAMSETE trial evaluating RAD001 (everolimus) in advanced and metastatic silent neuroendocrine tumors; results were posted in January 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor
• Non-functioning Neuroendocrine Tumor

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced and Metastatic Silent Neuro-Endocrine Tumors, Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-01-25